April 2012
- LRG mourns the loss of a great friend, Jeroen Pit
- GDOL Update: Speakers announced
- LRG Research Team meets in Leuven, Belgium: leaves with renewed energy & commitment to finding the cure for GIST
- Meet our new Montana local rep: Dirk Niebaum
- Cellular origin of GIST from the “good” cells’ perspective
- Alianza GIST meets in Miami
- And they’re off! 1st ‘Harness a Cure’ is a success
- NJ GIST gathering serves up support & smoothies
- NoCal GISTers meet!
- New report finds most hospital errors go unreported
- Happy Cancerversary to Brenda Bannon!
- Thomas G. Overley, 1952-2012: Toledo lawyer played guitar, sang in group
- Durham lived life with passion and pride
- Did You Hear? Did You Know?
- Arizona GISTers meet!
- Spunky Texan fought GIST bravely
- Calendar
Archive
July 2009
In vitro activity of sorafenib against imatinib- and sunitinib-resistant kinase mutations
Abstract 10500, Jonathan Fletcher, MD, Brigham and Women’s Hospital, Boston, MA (substituting for Mike Heinrich, MD OHSU). Both Fletcher and Heinrich are members of the LRG Research Team.
Jonathan Fletcher presented results showing that sorafenib has superior in vitro potency compared with imatinib or sunitinib against a panel of GIST-relevant mutant kinase cell lines and models. They found that unlike sunitinib, sorafenib is active against most imatinib-resistant secondary mutations involving the KIT activation loop (exon 17). In their abstract, Fletcher and Heinrich (Pictured left) suggest that sorafenib should be evaluated for clinical efficacy as a second-line treatment for GIST with a primary KIT exon 11 mutation that has become resistant to imatinib.
This research is funded in part by The Life Raft Group and the GIST Cancer Research Fund and results from collaboration between Oregon Health & Science University and Brigham and Women’s Hospital.
Abstract #: 10500
Wednesday 8 July, 2009